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Abstract
Background: Polycystic ovarian syndrome (PCOS) is an endocrine disorder that affects
women’s fertility and causes alterations such as obesity, insulin resistance, menstrual
irregularities, and polycystic ovaries. The results of the studies show that the issue of
vitamin D and vitamin D receptor (VDR) is controversial for PCOS susceptibility.
Objective: To investigate the association of BsmI polymorphism in the VDR gene with
metabolic parameters in obese PCOS women.
Materials and Methods: In this case-control study, 38 obese subjects with PCOS and
40 unrelated obese individuals were evaluated to determine the allelic and genotypic
frequency of BsmI variant by Polymerase Chain Reaction Restriction Fragment Length
Polymorphism method. Body Mass Index, parathyroid hormone, phosphorus, and
calcium were evaluated in all participants.
Results: BsmI (rs1544410), (A/G) AA, AG, GG, A, and G percentage of genotypic/allelic
frequencies were 65.8, 26.3, 7.9, 78.9, and 21.1 in cases and 57.5, 40, 2.5, 77.5, and 22.5
in controls, respectively. Statistical analysis revealed that the differences in genotypic
(p = 0.31)/allelic (p = 0.83) frequencies and dominant (p = 0.45)/recessive (p = 0.35)
models between the cases and controls were not significant. This study indicates no
association between the BsmI genotypes and metabolic parameters.
Conclusion: It can be concluded that VDR BsmI (rs1544410) Intron 8 (A > G) was not
associated with obesity along with PCOS susceptibility in the studied groups.
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1. Introduction
Vitamin D is present in many biological
processes and takes a leading role in hormonal and
metabolic disorders related to female reproductive
system such as Polycystic Ovarian Syndrome
(PCOS), which is considered as the most prevalent
female endocrine disorder (1, 2). Alterations in
insulin pathway, sex hormone production, calcium,
phosphorus, and parathyroid hormone (PTH)
hemostasis presented in PCOS are also shown
to be affected by vitamin D (3-5). The processes
brought about vitamin D are mediated via the
vitamin D receptor (VDR), a nuclear receptor
with a DNA-binding domain that acts through
vitamin D response elements (6, 7). In the VDR
gene, a number of allelic variations have been
described, including restriction fragment length
polymorphisms -which have an association with
some of the patterns presented by PCOS- such
as FokI (C/T) (rs10735810/rs2228570), BsmI (A/G)
(rs1544410), ApaI (A/C) (rs7975232), Tru9I (G/A)
(rs757343), and TaqI (T/C) (rs731236). The BsmI
SNP is located in intron 8 near the 3’end of the
VDR gene. It may affect the VDR translation activity
or mRNA stability (8).
The finding of Mahmoudi and colleagues
demonstrated a significant association between
VDR BsmI “Bb” genotype and insulin resistance
in women with PCOS (9). The result of a study
in south India also illustrated the association
between BsmI A/G (rs1544410) and PCOS risk
in women (10). However, in other studies such
as the one conducted on Iranian Azeri Turkish
women, no significant differences were observed
in the genotypic/allelic frequencies between the
cases and controls regarding BsmI (rs1544410) (11).
Vitamin D plays an important role in regulating
calcium-phosphorus homeostasis. Irregularity
in calcium balance may lead to disruption of
follicular development in women and hence
affect the pathogenesis of PCOS (12). Studies
show that vitamin D deficiency can be a cause
of metabolic syndrome and insulin resistance in
PCOS, however, whether vitamin D is linked to
endocrine and fertility parameters in subjects with
PCOS is unclear (13, 14).
Therefore, due to the effect of serum levels of
PTH and phosphorus on PCOS, as well as the
role of calcium in oocyte maturation and early
embryonic development, the present study was
designed to investigate the possible associations
among the BsmI variant of VDR gene and PTH,
phosphorus, and calcium of obese women with
PCOS in a sample of Iranian population.
2. Materials and Methods
2.1. Design and participants
This case-control study was conducted at
the Isfahan Fertility and Infertility Center (IVF
center), Isfahan, Iran, during May-September
2016; 38 obese women with PCOS as the case
group and 40 obese women without PCOS as
a control group, both aged 18-40 yr, and Body
Mass Index (BMI) > 30 were enrolled in the study.
The presence of menstrual disorders such as
oligomenorrhea (six or fewer menses per year),
amenorrhea (no menses in the last six months),
hyper-androgenism (clinical-biochemical signs)
like hirsutism (Ferriman-Gallwey score ≥ 6),
acne, or alopecia and elevated androgen levels
(testosterone normal range < 0.77 ng/ml and free
testosterone normal range < 3.18 pg/ml) confirmed
the diagnosis of PCOS. While the patient group
included obese women with BMI ≥ 30, had
PCOS, were married and infertile, and had
no familial history of PCOS, the control group
included healthy obese women with BMI ≥ 30,
married, with or without children and also without
a family history of PCOS. However, women
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diagnosed with PCOS and those from the control
group who had been on medications known to
affect the endocrinal system, carbohydrate, lipid,
and calcium metabolism for more than three
months prior to the initiation of the study were
excluded.
2.2. Biochemical measurements
Blood samples were collected from the control
group between days 2 and 6 of a menstrual cycle
or during a spontaneous bleeding episode and
progestin-induced menstrual cycle in patients
with PCOS. Overnight fasting blood samples
were collected and instantly centrifuged. Next,
sera were isolated and frozen at -20°C until
analyzed. PTH Intact AccuBind ELISA Kits (#9025-
300, Monobind Inc.USA) was used to measure
the concentration of PTH in serum samples
from all 78 participants. Serum level of calcium
and phosphorus was quantified with Calcium
Colorimetric Assay Kit (#K380-250, BioVision
Inc, USA) and Phosphorus (Pi) Colorimetric
Assay Kit (#E-BC-K245-S, Elabscience, China),
respectively.
For DNA analysis, blood samples were collected
in tubes containing EDTA and stored at 4°C.
Genomic DNA was purified from whole blood
using a commercial isolation kit (Iraizol#1004,
RNA Biotechnology Company, Iran). Genotypes
of VDR BsmI in intron 8 A/G (rs1544410) were
determined using the Polymerase Chain Reaction
Restriction Fragment Length Polymorphism (PCR-
RFLP) method in subjects with/without PCOS.
The optimized primer pair sequences were 5’-
GGAGACACAGATAAGGAAATAC-3’ as BsmI-F and
5’-CCGCAAGAAACCTCAAATAACA-3’ as BsmI-R.
The PCR amplification was carried out in a BIO
RAD system (T100TM Thermal Cycler). Twenty ml
of the PCR reaction system consisted of 10 µl Taq
2X Master Mix with 1.5 mM MgCl2 (# A180306,
AMPLIQON, Denmark) 10 pmol of each BsmI-
F and BsmI-Rprimers and 10 ng genomic DNA.
PCR was performed with an initial denaturation
at 96°C for 5 min, followed by 35 cycles of
denaturation at 94°C for 45 sec, annealing at 60°C
for 45 sec, and extension at 72°C for 45 sec.
The final extension was at 72°C for 5 min. PCR
products were separated in 2% agarose gel. The
length of PCR product was 248 bp. Enzymatic
digestion was performed by the BsmI (#R0134S,
New England Biolabs) enzyme in accordance
with the manufacturer’s instructions. The BsmI
polymorphic site revealed two possible alleles,
allele B/A (absence of a restriction site) and b/G
(presence of a restriction site). The genotypes were
defined as BB (one band at 248 bp), bb (two bands
at 73 and 175 bp), or Bb (three bands at 248, 73,
and 175 bp) (Figure 1).
Figure 1. Restriction pattern of VDR gene fragment with BsmI, M: Marker.
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2.3. Ethical consideration
The study was approved by the Research
Committee of Islamic Azad University,
Falavarjan Branch (Code: 17230520942004).
Informed consent was obtained from all
participants.
2.4. Statistical analysis
Chi-square test (χ2) was used to compare the
distribution of the allele and genotype frequencies
and determination of Hardy-Weinberg equilibrium
for BsmI polymorphism. The χ2 value was
calculated using the Statistical Package for
the Social Sciences, version 20.0, SPSS Inc,
Chicago, Illinois, USA (SPSS). Additionally,
independent 𝑡 test and Man-Whitney test
were used to detect the differences between
the cases and controls in respect to their
characteristics (p < 0.05), and the result was
statistically significant.
3. Results
Table I summarizes the characteristics of the
subjects with and without PCOS. In our study,
the mean age of the 38 participants with PCOS
was 28.58 ± 5.83 yr, and the mean age of
40 controls was 31.34 ± 5.5 yr (p < 0.001).
There were no significant differences between
women with PCOS and controls regarding clinical
characteristics such as BMI (p = 0.072), serum level
of PTH (p = 0.32), serum level of calcium (p = 0.79),
and phosphorus (p = 0.61).
Table II demonstrates the allelic and genotypic
frequencies of VDR BsmI polymorphism in intron 8
(A/G) (rs1544410). VDR BsmI genotypic distribution
in controls were in Hardy-Weinberg equilibrium
(χ2 = 0.864, p = 0.52). The B and b alleles’
frequencies of VDR BsmI polymorphism were
78.9% and 21.1% in cases and 77.5% and 22.5% in
controls regarding the “A” and “G” alleles. Also,
the frequencies of BB, Bb, and bb genotypes
of the BsmI variant were 65.8%, 26.3%, and
7.9% in cases and 57.5%, 40%, and 2.5% in
controls, respectively. There were no significant
differences in genotypes (p = 0.31) and allele
(p = 0.83) frequencies between the obese PCOS
and obese healthy controls. According to result
of the Fisher’s exact test and χ2, recessive
(p = 0.35) and dominant (p = 0.45) genotypes
did not show any significant association with the
disease.
Table III presents the distribution of serum level
of PTH, calcium, and phosphorus according to
the genotypes observed in individuals with and
without PCOS. Because of the limited frequencies
of genotype bb in the VDR BsmI polymorphism,
we combined Bb and bb genotypes as a group.
Control women with BB genotype were found
to have a relatively higher mean than those
with Bb + bb genotype. However, none of the
biochemical traits showed significant differences
with respect to the BsmI genotypes (Table III).
Although, the level of serum PTH was significantly
different between women with BB genotype and
bb + Bb among control group (p = 0.04), the level
of PTH showed no significant differences among
women with PCOS with BB or Bb + bb genotypes
(p = 0.88) (Table III). The level of phosphorus and
calcium in women with different genotype BB and
Bb + bb in both case and health control groups
demonstrated no significant elevation.
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Table I. The clinical characteristics of PCOS women
Cases Controls P-value
Number of subjects 38 40 -
Age (Yr) 28.58 ± 5.83 31.34 ± 5.5 < 0.001𝑎
BMI (kg/m2) 33.82 ± 3.39 32.39 ± 3.32 0.07𝑎
Serum level of PTH (pg/ml) 31.36 ± 12.67 19.42 ± 10.07 0.32𝑏
Serum level of calcium (mg/dl) 9.61 ± 0.48 9.59 ± 0.55 0.79𝑏
Serum level of phosphorus (mg/dl) 3.35 ± 0.4 3.49 ± 0.44 0.61𝑏
BMI: Body mass index; PTH: Parathyroid hormone, 𝑎Independent sample t test and 𝑏Mann-Whitney test
Table II. Allelic and genotypic frequencies of VDR BsmI in cases and controls
Controls Cases
Number (%) Number (%)
P-value
Allele
B (A) 62 (77.5) 60 (78.9)
b (G) 18 (22.5) 16 (21.1)
Total 80 (100) 76 (100)
0.83𝑎
Genotype
BB (AA) 23 (57.5) 25 (65.8)
Bb (AG) 16 (40.0) 10 (26.3)
Bb (GG) 1 (2.5) 3 (7.9)
Total 40 (100) 38 (100)
0.31𝑏
Recessive
BB + Bb 39 (97.5) 35 (92.1)
bb 1 (2.5) 3 (7.9)
Total 40 (100) 38 (100)
0.35𝑏
Dominant
BB 23 (57.5) 25 (65.8)
Bb + bb 17 (42.5) 13 (34.2)
Total 40 (100) 38 (100)
0.45𝑎
𝑎Chi-square test and 𝑏Fisher’s exact test
Table III. BsmI polymorphism and PTH (pg/ml), Ca (mg/dl), P (mg/dl)
Bb + bb BB P-value𝑎
Cases
PTH 26.76 ± 13.89 32.76 ± 17.95 0.88
Ca 9.54 ± 0.53 9.64 ± 0.46 0.57
P 3.45 ± 0.46 3.58 ± 0.37 0.31
Controls
PTH 26.98 ± 14.99 13.83 ± 8.91 0.04
Ca 9.49 ± 0.45 9.67 ± 0.61 0.43
P 3.49 ± 0.56 3.48 ± 0.35 0.67
PTH: Parathyroid hormone; Ca: Calcium; P: Phosphorus; 𝑎 Mann-Whitney test
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4. Discussion
In this study, we examined the BsmI
polymorphism among obese women with and
without PCOS as cases and controls, respectively,
and tested for their association with PTH, Ca, and
P phenotypes. BsmI polymorphism in the VDR
gene is located on the 3’ regulatory region. The
three adjacent RFLP for BsmI, ApaI, and TaqI,
which are located near the 3’ end of the gene is
known to be involved in regulating expression,
particularly through the control of mRNA stability
(15). Therefore, the frequency of BsmI genotypes
and alleles seem to play a role in the disease.
Although, in our study, there was no significant
difference in B and b alleles and genotypes
between the control and patient groups, the
results of other populations were different. In our
population, BB genotype was more frequent in
both groups than other genotypes. However, there
was no significant difference in the dominant and
recessive models in the studied groups.
The results of studies on VDR gene
polymorphisms in other populations showed an
association of VDR BsmI A/G, ApaI A/C, and TaqI
T/C SNPs with PCOS risk in South Indian women
(10). Moreover, the result of a study by Mahmoudi
and colleagues in 35 Iranian women with PCOS in
2015 determined an association between the VDR
gene BsmI and ApaI polymorphisms and PCOS
risk (9). Another study, conducted by Mahmoudi,
focused on finding an association between the
FokI, BsmI, ApaI, TaqI polymorphisms and PCOS.
This study selected 162 patients aged 19-42 yr,
diagnosed according to the National Institute of
Child Health and Human Development criteria.
In his research, he reported that the VDR gene
ApaI polymorphism is associated with PCOS (1).
Bagheri and colleagues studied the FokI and BsmI
variations of the VDR gene in genetic susceptibility
to PCOS in 46 Iranian, Azeri Turkish women.
Their results showed no significant differences
with PCOS susceptibility in the studied group (11).
Further, Ranjzad and colleagues investigated a
possible relation between the FokI, BsmI, ApaI,
TaqI, and Tru9I polymorphisms with biochemical
and metabolic parameters in 56 Iranian PCOS
women. Results revealed significant associations
between decreased levels of sex hormone
binding globulin (SHBG) and both VDR BsmI “GG”
(p = 0.009) and adiponectin (ADIPOQ) BsmI “CC”
(p = 0.016) genotypes, suggesting that the “G”
allele in homozygous is a risk factor for PCOS (16).
Additionally, the results of a meta-analysis study
by Han and co-workers suggested that VDR BsmI
variant G allele might be a susceptibility marker
of metabolic syndrome and VDR TaqI variant C
allele might be a susceptibility marker of PCOS (17).
Wehr and co-authors carried out a cohort study
including 545 women from Austria with PCOS
in order to investigate the association between
VDR polymorphisms and PCOS susceptibility.
Their research results revealed no association
of VDR BsmI, FokI, and TaqI polymorphisms
with anthropometric, endocrine, or metabolic
parameters (18).
Also, the results obtained by Jedrzejul
and colleagues were suggestive of a lack of
association among the homogeneous classic
PCOS phenotype, vitamin D deficiency, and VDR
gene polymorphisms in lower Silesian women
(19). Of course, several research/studies have
been performed on the relationship between
VDR gene polymorphisms and PCOS disease
in various populations, which showed some
association beside some lack of association (20-
23). In accordance with our study, Kumar and
co-workers showed that VDR BsmI (rs1544410)
intron 8 (A/G) were not associated with PCOS
susceptibility in Indian women population (24). In
another study on the same population as studied
by us, it was found that TaqI polymorphism
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was not associated with the risk of PCOS
(25). The results of various studies indicated
that the relationship between VDR gene
polymorphisms and PCOS among different
ethnicities was controversial (4). On the other
hand, in the Iranian population, studies have
been conducted on the association of microRNAs
(miRNA) that indicate the association with PCOS
(26).
Since vitamin D and its metabolites are
responsible for gene expression containing
vitamin D response elements including PTH (27),
there seems to be an association between the
VDR gene variants and PTH secretion. However,
in our study, there was no significant association
between the BsmI genotypes and serum PTH
levels. Findings of Zˇofkova and colleagues
showed that FokI polymorphism of the VDR
gene is closely related to the magnitude of PTH
secretion and/or degradation in postmenopausal
women (28). Although studies have reported that
women with PCOS (29, 30) had a higher level
of PTH and phosphorus, in our study, obese
women with Bb + bb genotype in control group
had higher serum levels than obese women
with BB genotype. There was also no significant
difference in serum calcium and phosphorus levels
between the control and patient groups in any of
the genotypic groupings.
Nevertheless, the present study had several
limitations. For example, its sample size and our
lack of information on other VDR polymorphisms,
which could have affected the results obtained in
the study.
5. Conclusion
This study revealed that BsmI (rs1544410) in
intron 8 of VDR gene has no associationwith obese
PCOS patients in our population.
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